Kevin K. Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin K. Brown has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Vincent Cottin
Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre de référence des maladies pulmonaires rares, Service de pneumologie, ERN-LUNG, INRAE, UMR754, Lyon, France
6 shared publications - Jeffrey James Swigris
Center for Interstitial Lung Disease, National Jewish Health, Denver, Colorado; and
5 shared publications - Joshua J. Solomon
Center for Interstitial Lung Disease, National Jewish Health, Denver, CO, USA
5 shared publications Athol U. Wells
National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
3 shared publicationsRozsa Schlenker-Herceg
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
3 shared publications- Yoshikazu Inoue
Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Osaka, Japan
3 shared publications
Latest Publications
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1506
Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1506
Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1036
Somatic Mutations of MUC5B Within Lung Tissue in Idiopathic Pulmonary Fibrosis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1036
Somatic Mutations of MUC5B Within Lung Tissue in Idiopathic Pulmonary Fibrosis
- 12 April 2023
- Published by Springer Nature
- p. 207-221
Rheumatoid Arthritis and the Lungs
- 12 April 2023
- Published by Springer Nature
- p. 241-250
Interstitial Pneumonia with Autoimmune Features
- 11 April 2023
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 43 (2)
Interstitial Lung Disease: 150 Years of Progress
- 11 April 2023
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 43 (2)
Interstitial Lung Disease: 150 Years of Progress
- Open Access
- 15 January 2023
- Published by Wiley in Respirology
- Vol. 28 (5) , 465-474
Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
Background and Objective: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We analysed the effects of nintedanib in the subset of Asian subjects.Methods: Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis who had shown progression of ILD at any time within the prior 24 months despite management deemed appropriate in clinical practice were randomized to receive nintedanib or placebo. We analysed the rate of decline in FVC (ml/year) over 52 weeks in all Asian subjects and in Asian subjects with a usual interstitial pneumonia (UIP)‐like fibrotic pattern on high‐resolution computed tomography (HRCT).Results: One hundred sixty‐four subjects in the INBUILD trial were of Asian race. The rate of decline in FVC (ml/year) over 52 weeks in this subgroup was −116.8 in the nintedanib group and −207.9 in the placebo group (difference: 91.0 [95% CI: 8.1, 173.9]; nominal p = 0.03). In Asian subjects with a UIP‐like fibrotic pattern on HRCT, the rate of decline in FVC (ml/year) over 52 weeks was −130.1 in the nintedanib group and −224.2 in the placebo group (difference: 94.1 [5.5, 182.7]; nominal p = 0.04). Adverse events led to treatment discontinuation in 19.0% of the nintedanib group and 13.8% of the placebo group.Conclusion: In Asian patients with progressive fibrosing ILDs, nintedanib reduced the rate of decline in FVC with adverse events that were manageable for most patients.
- 15 January 2023
- Published by Wiley in Respirology
- Vol. 28 (5) , 465-474
Open AccessNintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
Background and Objective: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We analysed the effects of nintedanib in the subset of Asian subjects.Methods: Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis who had shown progression of ILD at any time within the prior 24 months despite management deemed appropriate in clinical practice were randomized to receive nintedanib or placebo. We analysed the rate of decline in FVC (ml/year) over 52 weeks in all Asian subjects and in Asian subjects with a usual interstitial pneumonia (UIP)‐like fibrotic pattern on high‐resolution computed tomography (HRCT).Results: One hundred sixty‐four subjects in the INBUILD trial were of Asian race. The rate of decline in FVC (ml/year) over 52 weeks in this subgroup was −116.8 in the nintedanib group and −207.9 in the placebo group (difference: 91.0 [95% CI: 8.1, 173.9]; nominal p = 0.03). In Asian subjects with a UIP‐like fibrotic pattern on HRCT, the rate of decline in FVC (ml/year) over 52 weeks was −130.1 in the nintedanib group and −224.2 in the placebo group (difference: 94.1 [5.5, 182.7]; nominal p = 0.04). Adverse events led to treatment discontinuation in 19.0% of the nintedanib group and 13.8% of the placebo group.Conclusion: In Asian patients with progressive fibrosing ILDs, nintedanib reduced the rate of decline in FVC with adverse events that were manageable for most patients.
- Open Access
- 27 February 2022
- Published by Wiley in Respirology
- Vol. 27 (4) , 294-300
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
Background and objective: Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality.Methods: The relationships between baseline variables and time‐varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model.Results: Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1‐year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1‐unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1‐unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia‐like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1‐unit increase) was associated with lower risk.Conclusion: These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.
- 27 February 2022
- Published by Wiley in Respirology
- Vol. 27 (4) , 294-300
Open AccessPredictors of mortality in subjects with progressive fibrosing interstitial lung diseases
Background and objective: Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality.Methods: The relationships between baseline variables and time‐varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model.Results: Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1‐year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1‐unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1‐unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia‐like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1‐unit increase) was associated with lower risk.Conclusion: These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.
- Top Cited PapersOpen Access
- 2 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 59 (3) , 2004538
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Background The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib on ILD progression over the whole trial. Methods Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had ILD progression within the 24 months before screening despite management deemed appropriate in clinical practice, were randomised to receive nintedanib or placebo. Subjects continued on blinded randomised treatment until all subjects had completed the trial. Over the whole trial, mean±sd exposure to trial medication was 15.6±7.2 and 16.8±5.8 months in the nintedanib and placebo groups, respectively. Results In the nintedanib (n=332) and placebo (n=331) groups, respectively, the proportions of subjects who had ILD progression (absolute decline in FVC ≥10% predicted) or died were 40.4% and 54.7% in the overall population (hazard ratio (HR) 0.66, 95% CI 0.53–0.83; p=0.0003) and 43.7% and 55.8% among subjects with a usual interstitial pneumonia (UIP)-like fibrotic pattern on high-resolution computed tomography (HRCT) (HR 0.69, 95% CI 0.53–0.91; p=0.009). In the nintedanib and placebo groups, respectively, the proportions who had an acute exacerbation of ILD or died were 13.9% and 19.6% in the overall population (HR 0.67, 95% CI 0.46–0.98; p=0.04) and 15.0% and 22.8% among subjects with a UIP-like fibrotic pattern on HRCT (HR 0.62, 95% CI 0.39–0.97; p=0.03). Conclusion Based on data from the whole INBUILD trial, nintedanib reduced the risk of events indicating ILD progression. In patients with fibrosing ILDs other than IPF who had shown progression of ILD within the prior 2 years, events indicating further progression occurred frequently. Over a 16-month period, nintedanib reduced the risk of such events versus placebo.https://bit.ly/3yiZXnS
- 2 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 59 (3) , 2004538
Top Cited PapersOpen AccessNintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Background The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib on ILD progression over the whole trial. Methods Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had ILD progression within the 24 months before screening despite management deemed appropriate in clinical practice, were randomised to receive nintedanib or placebo. Subjects continued on blinded randomised treatment until all subjects had completed the trial. Over the whole trial, mean±sd exposure to trial medication was 15.6±7.2 and 16.8±5.8 months in the nintedanib and placebo groups, respectively. Results In the nintedanib (n=332) and placebo (n=331) groups, respectively, the proportions of subjects who had ILD progression (absolute decline in FVC ≥10% predicted) or died were 40.4% and 54.7% in the overall population (hazard ratio (HR) 0.66, 95% CI 0.53–0.83; p=0.0003) and 43.7% and 55.8% among subjects with a usual interstitial pneumonia (UIP)-like fibrotic pattern on high-resolution computed tomography (HRCT) (HR 0.69, 95% CI 0.53–0.91; p=0.009). In the nintedanib and placebo groups, respectively, the proportions who had an acute exacerbation of ILD or died were 13.9% and 19.6% in the overall population (HR 0.67, 95% CI 0.46–0.98; p=0.04) and 15.0% and 22.8% among subjects with a UIP-like fibrotic pattern on HRCT (HR 0.62, 95% CI 0.39–0.97; p=0.03). Conclusion Based on data from the whole INBUILD trial, nintedanib reduced the risk of events indicating ILD progression. In patients with fibrosing ILDs other than IPF who had shown progression of ILD within the prior 2 years, events indicating further progression occurred frequently. Over a 16-month period, nintedanib reduced the risk of such events versus placebo.https://bit.ly/3yiZXnS
- Open Access
- 17 December 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (6) , 2003967
Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”
No set of criteria will cover all patients, but the inclusion criteria used in the INBUILD trial were effective at identifying a population of patients with progressive ILDhttps://bit.ly/3mKkzzi
- 17 December 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (6) , 2003967
Open AccessReply to comment on “The natural history of progressive fibrosing interstitial lung diseases”
No set of criteria will cover all patients, but the inclusion criteria used in the INBUILD trial were effective at identifying a population of patients with progressive ILDhttps://bit.ly/3mKkzzi